Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glycomimetics Inc (NQ: GLYC )

0.3900 -0.0200 (-4.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glycomimetics Inc

< Previous 1 2 3 4 5 6 7 Next >
Why Is GlycoMimetics (GLYC) Stock Down 77% Today?
GlycoMimetics stock is falling on Monday with heavy trading of GLYC after posting lackluster results from a Phase 3 trial of uproleselan. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Monday morning! 
Via InvestorPlace
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
From GlycoMimetics, Inc.
Via Business Wire
Earnings Outlook For GlycoMimetics
Via Benzinga
Earnings Outlook For GlycoMimetics
Via Benzinga
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
From GlycoMimetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023
GLYC stock results show that GlycoMimetics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
From GlycoMimetics, Inc.
Via Business Wire
Earnings Scheduled For March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. 
Via Benzinga
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. 
Via Talk Markets
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
From GlycoMimetics, Inc.
Via Business Wire
Why Trinity Place Holdings Shares Are Trading Higher By 80%; Here Are 20 Stocks Moving Premarket
Shares of Trinity Place Holdings Inc. (NYSE: TPHS) rose sharply in pre-market trading. The company reported in 8K Filing, mortgage lender agreed to extend the mortgage loan forbearance period to Jan.... 
Via Benzinga
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
From Apollomics Inc.
Via GlobeNewswire
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
From GlycoMimetics, Inc.
Via Business Wire
Earnings Scheduled For November 3, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million. 
Via Benzinga
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
From GlycoMimetics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.